Influence of Heparin Dosage on Hemostasis under Combined Use of Nafamostat Mesilate during Deep Hypothermic Circulatory Arrest

Japanese Journal of Thoracic and Cardiovascular Surgery

Volumn 51, Issue 5, 2003, Pages 186-191

  Nakamura, Kunihide ^a   Onitsuka, Toshio ^a   Yano, Mitsuhiro ^a   Yano, Yoshikazu ^a   Matsuyama, Masakazu ^a   Niina, Katsuhiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Circulatory arrest; Deep hypothermia; Heparinization; Nafamostat mesilate

Indexed keywords

APROTININ; HEPARIN; NAFAMSTAT MESILATE; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; GUANIDINE DERIVATIVE; NAFAMSTAT;

ADULT; AGED; ALLERGIC REACTION; AORTA ARCH; AORTA SURGERY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART ARREST; HEART SURGERY; HEMOSTASIS; HEPARINIZATION; HUMAN; INDUCED HYPOTHERMIA; KIDNEY DISEASE; LOW DRUG DOSE; MALE; SURGICAL TECHNIQUE; THROMBOSIS; WOUND DRAINAGE; ARTICLE; CARDIOPULMONARY BYPASS; CRYOANESTHESIA; DOSE RESPONSE; MIDDLE AGED; THORACIC AORTA; THORACIC AORTA ANEURYSM;

AGED; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANIDINES; HEART ARREST, INDUCED; HEMOSTASIS; HEPARIN; HUMANS; HYPOTHERMIA, INDUCED; MALE; MIDDLE AGED;

EID: 0038160950     PISSN: 13444964     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-003-0029-0     Document Type: Conference Paper

References (19)

1. Reed RL 2nd, Bracey AW Jr, Hudson JD, Miller TA, Fischer RP. Hypothermia and blood coagulation: Dissociation between enzyme activity and clotting factor levels. Circ Shock 1990; 32: 141-52.
2. Westaby S. Coagulation disturbances in profound hypothermia: The influence of anti-fibrinolytic therapy. Semin Thorac Cardiovasc Surg 1997; 9: 246-56.
3. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1, esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981; 661: 342-5.
4. Miyamoto Y, Nakano S, Kaneko M, Takano H, Matsuda H. Clinical evaluation of a new synthetic protease inhibitor in open heart surgery: Effect on plasma serotonin and histamine release and blood conservation. ASAIO J 1992; 38: M395-8.
5. Nakamura K, Yano M, Onituska T. Hypothermic cardiopulmonary bypass using Nafamostat Mesilate for reducing the hemorrhage in operations on the total aortic arch. Jpn J Artif Organs 2000; 29: 365-8.
6. Douglas AS, McNicol GP, Bain WH, Mackey WA. The haemostatic defect following extracorporeal circulation. Brit J Surg 1966; 53: 455-67.
7. Kongsgaard UE, Smith-Erichsen N, Geiran O, Amundsen E, Mollnes TE, Garred P. Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery. Acta Anaesthesiol Scand 1989; 33: 343-7.
8. Campbell DJ, Dixson B, Kladis A, Kemme M, Santamaria JD. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1059-70.
9. Stibbe J, Kluft C, Brommer EJP, Gomes M, de Jong DS, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-82.
10. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71: 745-54.
11. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: Analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997; 113: 194-201.
12. Sundt TM III, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-24.
13. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-67.
14. Westaby S, Fomi A, Dunning J, Giannopoulos N, O'Regan D, Drossos G, et al. Aprotinin and bleeding in profoundly hypothermic perfusion. Eur J Cradiothorac Surg 1994; 8: 82-6.
15. Goldstein DJ, DeRosa CM, Mongero LB, Weinberg AD, Michler RE, Rose EA, et al. Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 1995; 110: 1615-21.
16. Rooney SJ, Bonser RS. The management of bleeding following surgery requiring hypothermic circulatory arrest. J Card Surg 1997; 12 (Suppl II): 238-42.
17. Royston D. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol 1996; 27(Suppl I): S42-9.
18. Usui A, Hiroura M, Kawamura M, Hibi M, Yoshida K, Murakami F, et al. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials. Ann Thorc Surg 1996; 62: 1404-11.
19. Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds LH Jr, Rao AK, et al. Nafamostat meislate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996; 75: 76-82.